Safety of biologics in psoriasis

Impact of anti-tumor necrosis factor-α agents on serum levels of KL-6 and surfactant protein-D in patients with psoriasis

(2017) Mitsuha Hayashi et al.   JOURNAL OF DERMATOLOGY

Psoriasis and comorbid diseases

(2017) Junko Takeshita et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature

(2017) Igor Snast et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease

(2016) Stephan R Targan et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

(2016) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Safety of secukinumab in the treatment of psoriasis

(2016) Andrew Blauvelt   Expert Opinion On Drug Safety

A Review of Psoriasis, Therapies, and Suicide

(2016) Melinda Gooderham et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study

(2016) Hideshi Torii et al.   JOURNAL OF DERMATOLOGY

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

(2016) Peter C.M. van de Kerkhof et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice

(2016) Eva Vilarrasa et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study

(2016) Marina Bagnoli et al.   LANCET ONCOLOGY

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

(2016) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Arthritis possibly induced and exacerbated by a tumour necrosis factor antagonist in a patient with psoriasis vulgaris

(2015) T. Takahashi et al.   BRITISH JOURNAL OF DERMATOLOGY

Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States

(2015) A.B. Kimball et al.   BRITISH JOURNAL OF DERMATOLOGY

Infliximab-induced autoantibodies: a multicenter study

(2015) João Luiz Pereira Vaz et al.   CLINICAL RHEUMATOLOGY

Infliximab-Related Infusion Reactions: Systematic Review

(2015) Lev Lichtenstein et al.   Journal of Crohns & Colitis

Infliximab and adalimumab, unlike ustekinumab, increase serum KL-6 levels in Japanese patients with psoriasis

(2015) Koichi Yanaba et al.   JOURNAL OF DERMATOLOGY

Interstitial pneumonia in two patients with psoriasis during ustekinumab treatment

(2015) Sota Kikuchi et al.   JOURNAL OF DERMATOLOGY

Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes

(2015) Denis Jullien et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries

(2015) Florence J. Dalgard et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study

(2015) Whan B. Kim et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice

(2015) Thierry Schaeverbeke et al.   RHEUMATOLOGY

Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations

(2015) Shunsuke Mori   WORLD JOURNAL OF GASTROENTEROLOGY

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis

(2015) Robert E. Kalb et al.   JAMA Dermatology

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection

(2015)   JOURNAL OF HEPATOLOGY

Elevation of serum KL-6 in patients with psoriasis treated with anti-tumour necrosis factor-α therapy

(2014) Y. Higashi et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Elevation of serum KL-6 levels during treatment with tumor necrosis factor-α inhibitor in patients with psoriasis

(2014) Tomotaka Mabuchi et al.   JOURNAL OF DERMATOLOGY

A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology

(2014) Akito Takamura et al.   Modern Rheumatology

Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs

(2014) Masayoshi Harigai et al.   Modern Rheumatology

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influence of Aggregation and Route of Injection on the Biodistribution of Mouse Serum Albumin

(2014) Grzegorz Kijanka et al.   PLoS One

The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C

(2013) H.-Y. Chiu et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

(2013) J. Schmitt et al.   BRITISH JOURNAL OF DERMATOLOGY

Antidrug antibodies in psoriasis: a systematic review

(2013) L. Hsu et al.   BRITISH JOURNAL OF DERMATOLOGY

Japanese guidance for use of biologics for psoriasis (the 2013 version)

(2013) Mamitaro Ohtsuki et al.   JOURNAL OF DERMATOLOGY

Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis

(2013) Eleanor J. Samarasekera et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis

(2013) Emmilia A. Dowlatshahi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

(2013) Pauline A. van Schouwenburg et al.   Nature Reviews Rheumatology

The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases

(2013) M. Jani et al.   RHEUMATOLOGY

Coronary Artery Disease in Patients With Psoriasis Referred for Coronary Angiography

(2012) April W. Armstrong et al.   AMERICAN JOURNAL OF CARDIOLOGY

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

(2012) Sandra Garcês et al.   ANNALS OF THE RHEUMATIC DISEASES

Biologic Therapies in the Treatment of Psoriasis: A Comprehensive Evidence-Based Basic Science and Clinical Review and a Practical Guide to Tuberculosis Monitoring

(2012) Raja K. Sivamani et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Immunogenicity of biological therapeutics

(2012) Charlotte Krieckaert et al.   CURRENT OPINION IN RHEUMATOLOGY

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

Detection and management of latent tuberculosis infections before biologic therapy for psoriasis

(2012) Paolo Amerio et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Pneumopathie interstitielle subaiguë après traitement d’un psoriasis par infliximab

(2011) S. Leger et al.   ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE

Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy

(2011) J Yun et al.   BRITISH JOURNAL OF CANCER

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

(2011) Tsen-Fang Tsai et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

(2011) Atsuyuki IGARASHI et al.   JOURNAL OF DERMATOLOGY

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis

(2011) Kenneth B. Gordon et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

(2011) Kenneth B. Gordon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Psoriasis and Hypertension Severity: Results from a Case-Control Study

(2011) April W. Armstrong et al.   PLoS One

Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases

(2011) Roberto Perez-Alvarez et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement

(2010) I. Solovic et al.   EUROPEAN RESPIRATORY JOURNAL

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial

(2010) Hideshi Torii et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

(2010) Akihiko ASAHINA et al.   JOURNAL OF DERMATOLOGY

A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti–interferon-alfa monoclonal antibody, in subjects with chronic psoriasis

(2010) Robert Bissonnette et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009

(2009) C.H. Smith et al.   BRITISH JOURNAL OF DERMATOLOGY

Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis

(2009) Heather R. Conti et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Psoriasis associated with ulcerative colitis and Crohn's disease

(2009) AD Cohen et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

How to systematically evaluate immunogenicity of therapeutic proteins – regulatory considerations

(2009) Eva-Maria Jahn et al.   New Biotechnology

Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment

(2009) Hirofumi Taki et al.   RHEUMATOLOGY INTERNATIONAL

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action

(2008) Angelique N. Collamer et al.   ARTHRITIS AND RHEUMATISM

Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice

(2008) Reiko Ito et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Review and expert opinion on prevention and treatment of infliximab-related infusion reactions

(2008) L.L.A. Lecluse et al.   BRITISH JOURNAL OF DERMATOLOGY

Regulation of inflammatory responses by IL-17F

(2008) Xuexian O. Yang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents

(2008) Sean D. Doherty et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tuberculosis in the age of biologic therapy

(2008) Claudia Hernandez et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY